A randomised trial to compare the toxicity and pharmacokinetics of three fixed-dose combination based antiretroviral regimens for treatment of human immunodeficiency virus (HIV) infected children in Africa.

Trial Profile

A randomised trial to compare the toxicity and pharmacokinetics of three fixed-dose combination based antiretroviral regimens for treatment of human immunodeficiency virus (HIV) infected children in Africa.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Efavirenz (Primary) ; Abacavir/lamivudine/nevirapine; Lamivudine/abacavir; Lamivudine/stavudine; Lamivudine/stavudine/nevirapine; Lamivudine/zidovudine; Lamivudine/zidovudine/nevirapine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CHAPAS-3
  • Most Recent Events

    • 16 Feb 2017 Results (n=249) investigating microbial translocation as a driver to Immune activation in Ugandan Children, presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 05 Oct 2016 Results of CHAPAS-1 and CHAPAS-3 trials published in the Journal of Antimicrobial Chemotherapy (2016).
    • 12 Apr 2016 Results from the PK sub-study(n=128) published in the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top